论文部分内容阅读
目的:1999年帕利珠单抗(Synagis(?))在瑞典注册,用于预防早产儿呼吸道合胞病毒(RSV)感染。由于费用高和人们对其有效性了解有限,怎样和何时应用就成了人们讨论的问题。于是2000年瑞典制定了帕利珠单抗使用指南。本研究就是为了评价该指南。方法:2000-2002年两次RSV流行期间在全国范围内进行了前瞻性研究。瑞典几家医院的儿科报道了帕利珠单抗的使用情
OBJECTIVE: In 1999, Synagis (?) Was registered in Sweden for the prevention of respiratory syncytial virus (RSV) infection in preterm infants. Due to the high cost and the limited understanding of their effectiveness, how and when to apply becomes a subject of discussion. So in 2000 Sweden developed a guideline for the use of palivizumab. This research is to evaluate this guideline. METHODS: A prospective study was conducted nationwide during the two RSV epidemic periods from 2000-2002. Paedizumab was reported in pediatrics in several hospitals in Sweden